Envestnet Asset Management
NTLA icon

Envestnet Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Envestnet Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Sell
105,211
-4,079
-4% -$57.1K ﹤0.01% 3240
2026
Q1 		$1.4M Buy
109,290
+35,262
+48% +$449K ﹤0.01% 3264
2025
Q4 		$666K Sell
74,028
-12,149
-14% -$167K ﹤0.01% 3511
2025
Q3 		$1.49M Buy
86,177
+16,766
+24% +$206K ﹤0.01% 3090
2025
Q2 		$651K Sell
69,411
-3,739
-5% -$30.7K ﹤0.01% 3518
2025
Q1 		$520K Buy
73,150
+6,496
+10% +$65.6K ﹤0.01% 3597
2024
Q4 		$777K Sell
66,654
-13,323
-17% -$208K ﹤0.01% 3329
2024
Q3 		$1.64M Buy
79,977
+24,421
+44% +$563K ﹤0.01% 2798
2024
Q2 		$1.24M Buy
55,556
+4,264
+8% +$102K ﹤0.01% 2885
2024
Q1 		$1.41M Buy
51,292
+2,036
+4% +$56.6K ﹤0.01% 2797
2023
Q4 		$1.5M Buy
49,256
+12,499
+34% +$359K ﹤0.01% 2644
2023
Q3 		$1.16M Buy
36,757
+17,500
+91% +$679K ﹤0.01% 2698
2023
Q2 		$785K Sell
19,257
-244
-1% -$9.89K ﹤0.01% 2930
2023
Q1 		$727K Buy
19,501
+967
+5% +$37.9K ﹤0.01% 2900
2022
Q4 		$647K Sell
18,534
-2,420
-12% -$115K ﹤0.01% 2945
2022
Q3 		$1.17M Sell
20,954
-366
-2% -$22.7K ﹤0.01% 2438
2022
Q2 		$1.1M Sell
21,320
-236
-1% -$12K ﹤0.01% 2509
2022
Q1 		$1.57M Sell
21,556
-3,676
-15% -$311K ﹤0.01% 2355
2021
Q4 		$2.98M Buy
25,232
+3,181
+14% +$398K ﹤0.01% 1909
2021
Q3 		$2.96M Buy
22,051
+769
+4% +$116K ﹤0.01% 1848
2021
Q2 		$3.45M Sell
21,282
-1,359
-6% -$106K ﹤0.01% 1732
2021
Q1 		$1.82M Buy
22,641
+7,213
+47% +$484K ﹤0.01% 1999
2020
Q4 		$839K Buy
+15,428
New +$560K ﹤0.01% 2338

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Envestnet Asset Management's NTLA Position: Q2 2026 in Review

Envestnet Asset Management reduced its Intellia Therapeutics (NTLA) stake by 3.7% in Q2 2026, selling an estimated $57.1K and leaving 105,211 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3240.

Envestnet Asset Management first reported a position in NTLA in Q4 2020 and has held it in 23 quarters since. The position peaked at $3.45M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Envestnet Asset Management held 105,211 shares of Intellia Therapeutics worth $1.78M as of Q2 2026.
  • Envestnet Asset Management sold 4,079 Intellia Therapeutics shares in Q2 2026, an estimated $57.1K.
  • Intellia Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3240 holding.
  • Envestnet Asset Management first reported a position in Intellia Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Envestnet Asset Management's Intellia Therapeutics position peaked at $3.45M in Q2 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.